Literature DB >> 14567086

[Bronchial carcinoma. Epidemiology, diagnosis and therapy].

H N Macha1.   

Abstract

Bronchial carcinoma still has a dark prognosis and therapeutic progress remains painfully slow: the 5-year survival rate raised in the last 20 years from 11 to 15%. There are no early symptoms by the tumor and detection by screening is not effective. Worldwide incidence is raising, the falling rates in men in the western world have been compensated by a steep increase in eastern Europe an Asia. Cigarette smoking is in 85% the main cause of this epidemic. Better understanding of genetic predisposition may identify patients at higher risk. Tumor in stage IA-IIB of non small cell carcinoma could gain by neoadjuvant chemotherapy, what is more probable for stage IIA and IIIB. Radiation therapy in combination with chemotherapy improves survival in inoperable stage IIIB. In stage IV disease palliative chemotherapy is superior to best supportive care.

Entities:  

Mesh:

Year:  2003        PMID: 14567086     DOI: 10.1007/s00108-003-0931-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

1.  Outcome of bronchial carcinoma in situ.

Authors:  B J Venmans; T J van Boxem; E F Smit; P E Postmus; T G Sutedja
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

2.  Lung cancer--time to move on from chemotherapy.

Authors:  Desmond N Carney
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

3.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.

Authors:  M Saunders; S Dische; A Barrett; A Harvey; G Griffiths; M Palmar
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

4.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

Authors:  W Sause; P Kolesar; I V Taylor S; D Johnson; R Livingston; R Komaki; B Emami; W Curran; R Byhardt; A R Dar; A Turrisi
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

5.  Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer.

Authors:  M Thomas; C Rübe; M Semik; M von Eiff; L Freitag; H N Macha; W Wagner; F Klinke; H H Scheld; N Willich; W E Berdel; K Junker
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

6.  Early Lung Cancer Action Project: overall design and findings from baseline screening.

Authors:  C I Henschke; D I McCauley; D F Yankelevitz; D P Naidich; G McGuinness; O S Miettinen; D M Libby; M W Pasmantier; J Koizumi; N K Altorki; J P Smith
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

7.  Economic decision analysis model of screening for lung cancer.

Authors:  D Marshall; K N Simpson; C C Earle; C W Chu
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

8.  Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography.

Authors:  M Kaneko; K Eguchi; H Ohmatsu; R Kakinuma; T Naruke; K Suemasu; N Moriyama
Journal:  Radiology       Date:  1996-12       Impact factor: 11.105

9.  A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China.

Authors:  Y L Qiao; M S Tockman; L Li; Y S Erozan; S X Yao; M J Barrett; W H Zhou; C A Giffen; X C Luo; P R Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-11       Impact factor: 4.254

10.  Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung.

Authors:  W P Luke; F G Pearson; T R Todd; G A Patterson; J D Cooper
Journal:  J Thorac Cardiovasc Surg       Date:  1986-01       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.